lymphadenopathy; this is a spontaneous report received from a contactable reporter (consumer) from the regulatory authority. the reporter is the patient. regulatory number: gb-mhra-webcovid-202202170655100250-i9era. other case identifier: gb-mhra-adr 26612325. a 37-year-old female patient (not pregnant) received bnt162b2 (comirnaty), administration date 31jan2022 (batch/lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. relevant medical history included: "suspected covid-19", start date: 06jun2021 (ongoing). the patient's concomitant medications were not reported. vaccination history included: covid-19 vaccine (dose 1; manufacturer unknown), for covid-19 immunization; covid-19 vaccine (dose 2; manufacturer unknown), for covid-19 immunization. on 01feb2022, the patient experienced lymphadenopathy (medically significant) with outcome of recovering. the patient underwent the following laboratory tests and procedures: sars-cov-2 test: (17jun2021) positive, notes: yes - positive covid-19 test; ultrasound lymph nodes: (unspecified date) reduced in size, notes: 2 weeks later; (unspecified date) 3 large reactive lymph nodes in clavicle & armpit. additional information: the patient had long covid through having covid 19jun2021. the patient is not currently breastfeeding. three large reactive lymph nodes in her clavicle and armpit ultrasound determined, two weeks later reducing in size. patient has not tested positive for covid-19 since having the vaccine. patient is not enrolled in clinical trial. no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected

test date: 20210617; test name: covid-19 virus test; test result: positive ; comments: yes - positive covid-19 test; test name: ultrasound; result unstructured data: test result:reduced in size; comments: 2 weeks later; test name: ultrasound; result unstructured data: test result:3 large reactive lymph nodes in clavicle & armpit

na

suspected covid-19